Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07600177Phase 4Recruiting
- Sponsor
- Oregon Health & Science University
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aficamten in hypertrophic cardiomyopathy (HCM), sponsored by Oregon Health & Science University. Started May 2026; status: recruiting.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT07600177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600177.